|
|
Profile
|
Delegates :
JEFFREY EDWARD MILLER |
|
Incorporated :
August 1 , 2015 |
Paid in Capital :
Million yen |
Employees :
10 人 |
Address :
Kawasaki-ku Tonomachi 3-25-13, Kawasaki-city KANAGAWA
〒210-0821
|
TEL/FAX :
+81-44-281-1500 / +81-3-6745-9346 |
URL：
https://invivoscribe.com/ |
Attachment :
|
Mission/Background :
LabPMM GK is the Japanese subsidiary of Invivoscrive Inc., a US-based company headquartered in San Diego.
We have obtained regulatory approval for the companion diagnostic test, "LeukoStrat CDx FLT3 Mutation
Assay," for acute myeloid leukemia (AML) and have been manufacturing and selling standardized in vitro
diagnostic kits domestically. Additionally, we have a commercial service lab that has received ISO 15189
certification and conducts LeukoStrat test service. We are actively advancing the development of genetic tests related to hematopoietic malignancies. |
|
Technology & Business
|
Our company offers the in vitro diagnostic product 'LeukoStrat CDx FLT3 Mutation Assay' kit and provides contract services for this assay.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
LeukoStrat CDx FLT3 Mutation Assay
|
Launched
|
FLT3 ITD/TKD mutation detection kit
|
|
LeukoStrat CDx FLT3 Mutation Assay Service
|
Launched
|
FLT3 ITD/TKD mutation detection assay service
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights
|
In 2023, we have developed a high-sensitivity FLT3 ITD MRD test using NGS to predict the prognosis of AML, and we are currently preparing to introduce the kit and service in Japan.
|
|
Alliance strategy
|
We can collaborate with pharmaceutical startups developing therapies for various diseases utilizing biomarkers, starting from the early stages of clinical development. Together, we can co-develop companion diagnostics using flow cytometry, PCR, and NGS. After clinical performance evaluation studies, we can introduce these diagnostic products to the global market.
|
|
|